Your browser is no longer supported. Please, upgrade your browser.
JAZZ Jazz Pharmaceuticals plc monthly Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals plc
Index- P/E17.35 EPS (ttm)8.02 Insider Own2.90% Shs Outstand56.95M Perf Week-0.01%
Market Cap7.93B Forward P/E8.04 EPS next Y17.31 Insider Trans2.06% Shs Float55.08M Perf Month8.99%
Income486.30M PEG0.93 EPS next Q3.58 Inst Own99.60% Short Float4.25% Perf Quarter10.51%
Sales1.95B P/S4.05 EPS this Y34.60% Inst Trans3.26% Short Ratio3.74 Perf Half Y-7.65%
Book/sh47.73 P/B2.92 EPS next Y16.55% ROA9.10% Target Price172.67 Perf Year-13.69%
Cash/sh14.62 P/C9.52 EPS next 5Y18.60% ROE17.10% 52W Range113.52 - 184.00 Perf YTD12.26%
Dividend- P/FCF9.75 EPS past 5Y15.80% ROI12.20% 52W High-24.37% Beta1.10
Dividend %- Quick Ratio3.00 Sales past 5Y16.70% Gross Margin93.80% 52W Low22.59% ATR4.00
Employees1360 Current Ratio3.20 Sales Q/Q14.30% Oper. Margin33.70% RSI (14)58.46 Volatility2.25% 2.64%
OptionableYes Debt/Eq0.59 EPS Q/Q95.10% Profit Margin24.90% Rel Volume0.43 Prev Close139.37
ShortableYes LT Debt/Eq0.57 EarningsMay 07 AMC Payout0.00% Avg Volume625.25K Price139.16
Recom1.90 SMA204.78% SMA502.58% SMA200-4.30% Volume271,119 Change-0.15%
Mar-20-19Initiated SunTrust Buy $163
Dec-14-18Initiated Wolfe Research Peer Perform
Nov-08-18Reiterated B. Riley FBR Buy $219 → $190
Aug-08-18Reiterated Stifel Buy $180 → $205
Jul-11-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-23-18Reiterated H.C. Wainwright Neutral $150 → $160
Mar-19-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-03-18Initiated Leerink Partners Outperform $180
Dec-05-17Reiterated Mizuho Neutral $144 → $150
Nov-10-17Resumed H.C. Wainwright Neutral $150
Nov-08-17Reiterated RBC Capital Mkts Outperform $210 → $195
Oct-19-17Initiated FBR & Co. Buy $206
Oct-05-17Initiated Morgan Stanley Equal-Weight $155
Sep-28-17Initiated Goldman Neutral $165
Aug-25-17Initiated H.C. Wainwright Neutral $144
May-31-17Reiterated Mizuho Neutral $150 → $144
May-15-17Initiated RBC Capital Mkts Outperform $210
Apr-06-17Downgrade Mizuho Buy → Neutral $162 → $150
Mar-21-17Reiterated Mizuho Buy $152 → $162
Feb-21-17Reiterated Mizuho Buy $127 → $152
May-17-19 09:10AM  Is Jazz Pharmaceuticals (JAZZ) Stock Undervalued Right Now? Zacks
May-16-19 04:30PM  Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress PR Newswire
May-13-19 09:07PM  Edited Transcript of JAZZ earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-10-19 09:55AM  3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates Zacks
08:45AM  3 Reasons Why Growth Investors Shouldn't Overlook Jazz (JAZZ) Zacks
May-09-19 08:00AM  Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019 PR Newswire
07:46AM  These 3 revolutionary genomics companies are changing lives for patients and investors MarketWatch
May-08-19 08:01AM  Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates Zacks +9.28%
06:00AM  Jazz Pharmaceuticals Hits All the Right Notes in Q1 Motley Fool
01:24AM  Jazz Pharmaceuticals (JAZZ) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 07:35PM  Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates Zacks
06:29PM  Jazz: 1Q Earnings Snapshot Associated Press
04:05PM  Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results PR Newswire
01:07PM  5 Stocks With Low Price-Earnings Ratios GuruFocus.com
May-06-19 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences PR Newswire
01:40PM  What Should Investors Know About Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Earnings Outlook? Simply Wall St.
May-02-19 09:30AM  JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now? Zacks
Apr-30-19 10:32AM  Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Apr-29-19 09:15AM  Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run? Zacks
Apr-23-19 04:05PM  Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019 PR Newswire
Apr-18-19 08:05PM  Are Hedge Funds Right About Jazz Pharmaceuticals? Insider Monkey
Apr-16-19 09:30AM  JAZZ vs. ZTS: Which Stock Is the Better Value Option? Zacks
08:47AM  Should We Be Cautious About Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) ROE Of 16%? Simply Wall St.
08:45AM  3 Reasons Why Jazz (JAZZ) Is a Great Growth Stock Zacks
Apr-11-19 09:46AM  Concert Pharma Initiates Early-Stage Schizophrenia Study Zacks
Apr-04-19 06:20PM  Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe Reuters
06:16PM  Drugmakers Jazz, Alexion, Lundbeck to pay $123 mln to resolve U.S. charity kickback probe Reuters
10:34AM  Jazz Pharma, Alexion and Lundbeck to pay $122.6 million to resolve kickback allegations MarketWatch
Apr-01-19 05:00AM  Stocks That Would Have Made You Rich Today GOBankingRates
Mar-28-19 09:30AM  Jazz (JAZZ) Down 0.4% Since Last Earnings Report: Can It Rebound? Zacks
Mar-27-19 04:30PM  Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study Zacks
07:52AM  The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO Benzinga
Mar-26-19 04:13PM  Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness PR Newswire
03:33PM  What Should Investors Know About The Future Of Jazz Pharmaceuticals plc's (NASDAQ:JAZZ)? Simply Wall St.
Mar-25-19 09:19AM  Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more American City Business Journals
Mar-21-19 07:51AM  The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering Benzinga
Mar-20-19 09:05PM  FDA approves Jazz Pharmaceuticals sleep disorder drug American City Business Journals
08:02PM  Jazz Pharma's sleep disorder treatment gets FDA nod Reuters
07:10PM  Jazz Pharma's sleep disorder treatment gets FDA nod Reuters
06:53PM  Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea PR Newswire
11:14AM  Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision Zacks
08:00AM  Here are the biggest analyst calls of the day: Lyft, Monster, FedEx, Rockwell Automation & more CNBC
Mar-19-19 11:09AM  FDA decision on Jazz Pharmaceuticals narcolepsy drug expected Wednesday American City Business Journals
Mar-12-19 09:56AM  Is Jazz Pharmaceuticals (JAZZ) a Good Value Investor Pick? Zacks
07:00AM  The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom Zacks
Mar-11-19 09:19AM  The Best And Worst Stocks of the 10-Year Bull Market Zacks
Mar-07-19 02:22PM  The 10 Best (and 10 Worst) Stocks of This 10-Year Bull Market Kiplinger
Mar-05-19 04:05PM  Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference PR Newswire
07:15AM  3 Best Biotech Bargain Stocks on the Market Right Now Motley Fool
Mar-01-19 12:08PM  Edited Transcript of JAZZ earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-28-19 11:24AM  Should You Take Comfort From Insider Transactions At Jazz Pharmaceuticals plc (NASDAQ:JAZZ)? Simply Wall St.
09:15AM  Too Much Talking, Not Enough Action Zacks
08:43AM  Jazz Pharmaceuticals (JAZZ) Surges: Stock Moves 7.9% Higher Zacks
Feb-27-19 08:13AM  The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings Benzinga +7.88%
07:13AM  Jazz Pharma (JAZZ) Q4 Earnings & Sales Beat, Stock Up 8% Zacks
02:08AM  Jazz Pharmaceuticals PLC (JAZZ) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-26-19 04:31PM  Jazz Pharma stock jumps 9% as biotech tops Wall Street Q4 views MarketWatch
04:05PM  Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results PR Newswire
02:30PM  Jazz Pharmaceuticals Plc to Host Earnings Call ACCESSWIRE
Feb-24-19 02:30PM  2 Stocks You Really Should Consider Shorting This Week TheStreet.com
Feb-20-19 03:09PM  Mylan (MYL) to Report Q4 Earnings: What's in the Offing? Zacks
Feb-15-19 08:10AM  New Research: Key Drivers of Growth for IPG Photonics, Keane Group, Jazz Pharmaceuticals, Tredegar, Carriage Services, and Surgery Partners Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-14-19 04:05PM  Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors PR Newswire
Feb-12-19 04:05PM  Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019 PR Newswire
09:53AM  Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings Zacks
Feb-06-19 10:10AM  Why Jazz (JAZZ) Could Beat Earnings Estimates Again Zacks
Jan-30-19 10:54AM  What Investors Should Know About Jazz Pharmaceuticals plcs (NASDAQ:JAZZ) Financial Strength Simply Wall St.
Jan-11-19 06:05AM  Edited Transcript of JAZZ earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-08-19 12:50PM  At biotech's big event, a chance for execs to shape LGBTQ diversity on boards American City Business Journals
Jan-06-19 06:01PM  3 Bargain Stocks You Can Buy Right Now Motley Fool
Jan-04-19 06:29PM  Jazz Inks Deal with Codiak to Develop Exosome Therapeutics Zacks
Jan-03-19 04:05PM  Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers PR Newswire
Jan-02-19 08:48AM  Should Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Be Your Next Stock Pick? Simply Wall St.
Dec-26-18 06:36AM  3 of the Cheapest Drug Stocks You Can Buy in 2019 Motley Fool
Dec-24-18 10:08AM  Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA Zacks
Dec-21-18 04:25PM  Pharma Stock Dives On Delayed Drug Is The Reaction 'Outsized'? Investor's Business Daily -11.29%
07:00AM  Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea PR Newswire
Dec-20-18 06:00AM  3 Top Healthcare Stocks to Buy in December Motley Fool
Dec-19-18 04:05PM  Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 7 PR Newswire
Dec-11-18 05:44PM  Jazz (JAZZ) Increases Share Buyback Authorization by $400M Zacks
08:22AM  The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings Benzinga
05:00AM  All That JAZZ MoneyShow
12:04AM  Jazz Pharmaceuticals Public Limited Company (JAZZ): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-10-18 04:10PM  Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million PR Newswire
Dec-05-18 11:45AM  Is Jazz Pharmaceuticals plcs (NASDAQ:JAZZ) CEO Salary Justified? Simply Wall St.
Nov-29-18 08:30AM  Report: Exploring Fundamental Drivers Behind Jazz Pharmaceuticals, 58, Encore Capital Group, Churchill Downs, Addus HomeCare, and Huntington Ingalls Industries New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
08:00AM  Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia PR Newswire
Nov-28-18 08:00AM  Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting PR Newswire
Nov-14-18 03:47PM  Edited Transcript of JAZZ earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -5.91%
Nov-13-18 06:26AM  Moving Average Crossover Alert: Jazz Pharmaceuticals (JAZZ) Zacks
Nov-09-18 02:00AM  Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea PR Newswire
Nov-08-18 10:09AM  Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View Zacks
Nov-07-18 07:05PM  National Institute for Health and Care Excellence (NICE) Recommends Jazz Pharmaceuticals' Vyxeos® (Daunorubicin and Cytarabine) for Adults with Specific Types of Secondary Acute Myeloid Leukaemia (AML) PR Newswire -14.60%
04:11PM  IBD 50 Pharma Stock Topples As Cancer Drug Lags Expectations Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences PR Newswire
03:45PM  Why Jazz Pharmaceuticals plc Stock Is Slumping Today Motley Fool
07:09AM  Dow Jones Futures Jump On Election Results; 7 Big Movers On Earnings Investor's Business Daily
Nov-06-18 07:40PM  Jazz Pharmaceuticals (JAZZ) Tops Q3 Earnings Estimates Zacks
06:41PM  Jazz: 3Q Earnings Snapshot Associated Press
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also develops Solriamfetol for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea, as well as in Phase II clinical trial for EDS associated with Parkinson's disease; Vyxeos for acute myeloid leukemia; and JZP-258 to treat EDS and cataplexy with narcolepsy and potential treatment of idiopathic hypersomnia and a chronic neurological disorder. In addition, it sells psychiatry and other products. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; and XL-protein GmbH. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Treacy PaulSVP, Technical OperationsMar 06Sale135.411,060143,53520,649Mar 07 07:18 PM
Young Matthew P.EVP & CFOMar 06Sale135.411,152155,99236,200Mar 07 07:13 PM
Treacy PaulSVP, Technical OperationsMar 01Sale139.50874121,92321,709Mar 04 07:41 PM
Hooper Suzanne SawochkaEVP & General CounselFeb 27Option Exercise46.836,666312,16946,404Feb 27 09:10 PM
Hooper Suzanne SawochkaEVP & General CounselFeb 27Sale140.006,666933,24039,738Feb 27 09:10 PM
Young Matthew P.EVP & CFOFeb 27Sale137.91884121,91227,967Feb 27 08:38 PM
Young Matthew P.EVP & CFOFeb 26Sale125.931,032129,96029,885Feb 27 08:38 PM
Hooper Suzanne SawochkaEVP & General CounselDec 14Option Exercise46.833,295154,30544,518Dec 14 06:04 PM
Hooper Suzanne SawochkaEVP & General CounselDec 14Sale140.213,334467,46041,184Dec 14 06:04 PM
COZADD BRUCE CChairman & CEODec 03Sale151.781,000151,780277,688Dec 06 04:35 PM
Young Matthew P.EVP & CFONov 23Sale150.00700105,00032,068Nov 27 04:54 PM
Mulligan SeamusDirectorNov 15Buy144.5650,0007,228,0011,100,868Nov 19 05:32 PM
MILLER MICHAEL PATRICKEVP, US CommercialNov 13Sale149.2720029,85424,972Nov 14 08:08 PM
COZADD BRUCE CChairman & CEONov 01Sale159.451,300207,290278,615Nov 05 06:48 PM
Young Matthew P.EVP & CFOOct 15Sale158.08700110,65832,768Oct 17 04:29 PM
MILLER MICHAEL PATRICKEVP, US CommercialOct 12Sale158.4620031,69225,172Oct 16 04:28 PM
COZADD BRUCE CChairman & CEOOct 01Sale167.991,300218,387279,915Oct 03 04:42 PM
COZADD BRUCE CChairman & CEOSep 21Sale164.361,300213,668281,215Sep 25 06:02 PM
Young Matthew P.EVP & CFOSep 17Sale162.70700113,89033,468Sep 19 05:05 PM
MILLER MICHAEL PATRICKEVP, US CommercialSep 14Sale165.2020033,04025,372Sep 17 06:06 PM
ENRIGHT PATRICK GDirectorSep 06Option Exercise139.1010,1301,409,09426,599Sep 07 04:30 PM
ENRIGHT PATRICK GDirectorSep 06Sale168.7610,1301,709,56516,469Sep 07 04:30 PM
Young Matthew P.EVP & CFOAug 15Sale176.05700123,23534,168Aug 16 06:57 PM
MILLER MICHAEL PATRICKEVP, US CommercialAug 14Sale175.7020035,14025,572Aug 16 04:52 PM
Treacy PaulSVP, Technical OperationsAug 10Sale176.611,309231,18317,458Aug 13 07:03 PM
BERNS PAUL LDirectorAug 10Sale176.61660116,5636,772Aug 13 06:52 PM
Gray PeterDirectorAug 10Sale176.61715126,2778,182Aug 13 06:47 PM
O'Keefe Kenneth WDirectorAug 10Sale176.61660116,5634,450Aug 13 06:42 PM
McSharry Heather AnnDirectorAug 10Sale176.61715126,2767,504Aug 13 06:38 PM
Schnee ElmarDirectorAug 10Sale176.61742131,0456,094Aug 13 06:23 PM
Sohn Catherine A.DirectorAug 10Sale176.61660116,5637,654Aug 13 06:20 PM
ENRIGHT PATRICK GDirectorAug 10Sale175.131,365239,05716,469Aug 13 06:13 PM
Winningham Rick EDirectorAug 10Sale176.61660116,5634,950Aug 13 06:05 PM
RIEDEL NORBERT GDirectorAug 10Sale176.61660116,5636,491Aug 13 07:57 PM
Winningham Rick EDirectorAug 09Option Exercise64.309,000578,65520,094Aug 13 06:05 PM
Winningham Rick EDirectorAug 09Sale176.1615,9792,814,8385,610Aug 13 06:05 PM
COZADD BRUCE CChairman & CEOAug 01Sale173.901,600278,240282,515Aug 03 06:21 PM
Young Matthew P.EVP & CFOJul 16Sale176.06700123,24234,868Jul 18 05:06 PM
MILLER MICHAEL PATRICKEVP, US CommercialJul 13Sale179.1520035,83025,772Jul 17 04:44 PM
COZADD BRUCE CChairman & CEOJul 02Sale170.811,600273,296284,115Jul 05 04:33 PM
Young Matthew P.EVP & CFOJun 15Sale176.99700123,89335,568Jun 19 04:26 PM
MILLER MICHAEL PATRICKEVP, US CommercialJun 14Sale176.5320035,30625,972Jun 18 04:37 PM
Young Matthew P.EVP & CFOJun 01Option Exercise58.725,000293,60041,268Jun 05 06:52 PM
Young Matthew P.EVP & CFOJun 01Sale170.045,000850,21236,268Jun 05 06:52 PM
COZADD BRUCE CChairman & CEOJun 01Sale168.867,0001,182,040285,715Jun 05 06:50 PM